All News
Filter News
Found 192 articles
-
Please check out the biopharma industry's COVID-19 stories that are trending for April 13, 2021.
-
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
-
Pyxis Bags $152 Million to Advance ADCs Licensed from Pfizer, LegoChem
3/31/2021
Pyxis Oncology raised $152 million in a Series B financing round to advance its differentiated portfolio of antibody-drug conjugates licensed from Pfizer earlier this month.
-
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
3/30/2021
Pyxis Oncology ("Pyxis" or the "Company") today announced the closing of a $152 million Series B financing, led by Arix Bioscience and co-led by RTW Investments, LP, with participation from additional new investors, including Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management,
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results
3/30/2021
Eledon Pharmaceuticals, Inc., (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today reported its fourth quarter and full-year 2020 operating and financial results.
-
Yesterday marked the close of three new financing rounds in the biotech space. Although none of today’s are that large, there is still plenty of money on the move. Here’s a look.
-
Acepodia Completes $47 Million Series B Financing to Advance Pipeline of Allogeneic Cell Therapy CandidatesPrograms receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates
3/16/2021
Acepodia, a biotechnology company developing next generation solid tumor and hematologic cancer cell therapies, today announced the closing of its $47 million Series B financing.
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
-
Merck and Ridgeback Biotherapeutics announced preliminary results from Ridgeback’s Phase IIa trial of molnupiravir in COVID-19.
-
Clinical Catch-Up: March 1-5
3/8/2021
It was another busy week for clinical trial announcements. Here’s a look. -
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
3/6/2021
The findings reported on a secondary objective to reduce time to negativity of infectious SARS-CoV-2 virus isolation from nasopharyngeal swabs from participants with symptomatic COVID-19
-
Caribou co-founder and CRISPR pioneer Jennifer Doudna said the company has leveraged its gene-editing technology platform to create a “promising clinical-stage therapeutic and a pipeline of pre-clinical allogeneic CAR-T and CAR-NK cell therapies that are potentially transformative for patients wi...
-
Ridgeback Biotherapeutics Announces Publication of Phase 1 Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Molnupiravir in Healthy Volunteers
3/3/2021
Ridgeback Biotherapeutics, LP today announced the publication of results from its first-in-human Phase 1 study of molnupiravir (EIDD-2801/MK-4482) in healthy volunteers.
-
Caribou Biosciences Raises $115M Series C Financing to Advance Next-Generation CRISPR Technologies and Allogeneic Cell Therapy Pipeline
3/3/2021
Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.
-
On Thursday, the company said the U.S. Food and Drug Administration wants to see additional data beyond the Phase III study announced last year.
-
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
2/24/2021
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS").
-
NORD Announces This Year's Heroes of Rare Disease: The 2021 Rare Impact Award Honorees
2/23/2021
June 28 virtual event to honor those making extraordinary strides to improve the lives of patients and families impacted by rare diseases
-
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
2/17/2021
– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza – – Functional genomics collaboration expanded to include respiratory viruses, Vir’s unique technology, and access to GSK’s small molecule compounds – – Additional exploration of up to three other antibodies for pathogens beyond influenza and coronaviruses
-
Butterfly Network, a Global Leader in Democratizing Medical Imaging, Closes Business Combination and Will Begin Trading on the New York Stock Exchange
2/16/2021
Announces unaudited 2020 full-year revenue of at least $45 million, representing growth of at least 63%, each above prior forecast